Clinical Trial

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days. The study will look at two different doses of DARE-HPV and two different treatment durations of 14 and 21 days compared to a placebo group or 14 or 21 days of treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2026-05-15; most recent amendment 2026-07-22.
Trial Details
NCT Number NCT07601074
Lead Sponsor Daré Bioscience, Inc.
Collaborators: Advanced Research Projects Agency for Health (ARPA-H)
Conditions Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
Enrollment 118 participants
Start Date 2026-06
Primary Completion 2027-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-23